Leading Justice is a full-service marketing company working with law firms on a cash-buy basis to sign up fully qualified, fraud-free Provigil and Nuvigil congenital malformation cases. Here at Leading Justice, we can custom tailor your firm’s Provigil and Nuvigil advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Provigil and Nuvigil birth defect advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that doesn’t qualify for the target campaign is evaluated to determine whether it qualifies for another type of claim. By using advanced approaches to target contacts specifically related to Provigil and Nuvigil and birth defects like cleft lip, cleft palate and congenital heart defects, Leading Justice will increase your firm’s Provigil and Nuvigil birth defect caseload. If you are interested in helping victims of Provigil and Nuvigil birth defects, our direct advertising strategies and extensive consumer reach at Leading Justice gives you the competitive edge and confidence you need to allocate your full budget, with the knowledge that your money is being spent in the best way possible.
Each law firm we work with at Leading Justice plays an important role in determining how we classify claims as qualified or not. And while our experience working with plaintiff law firms allows us to recognize a great case when we see one, we will customize our Provigil and Nuvigil birth defect intake specifications to the exact criteria you are seeking. So, if your firm has specific Provigil or Nuvigil qualifying case criteria you want us to use, we can train our intake specialists to apply the criteria to each phone call and email they receive. By eliminating the middle man, Leading Justice offers clients an opportunity for internal cash buys of Provigil and Nuvigil birth defect data with no chance of fraud.
Provigil and Nuvigil Birth Defect Litigation
Provigil (modafinil) and Nuvigil (armodafinil) are prescription sleep disorder medications designed to promote wakefulness in adults struggling with excessive sleepiness caused by narcolepsy, sleep apnea and shift work sleep disorder. When Provigil and Nuvigil were approved by the FDA, in 1998 and 2007 respectively, the agency designated both as pregnancy category C drugs, meaning that animal reproduction studies showed an adverse effect on the fetus. At the time, there weren’t enough human studies to determine whether the drugs posed a risk to babies exposed to Provigil or Nuvigil in utero and the drugs were regularly prescribed to pregnant women and women of childbearing age diagnosed with narcolepsy and sleep apnea. In 2009, a Provigil/Nuvigil Pregnancy Registry was established to evaluate the pregnancy and fetal outcomes associated with the use of Provigil and Nuvigil during pregnancy. In February 2019, the maker of Provigil and Nuvigil, Teva Pharmaceuticals, informed Health Canada that the results of the 2018 annual report of the ongoing pregnancy registry showed “a higher rate of major congenital anomalies, and other adverse reactions, in children exposed to [modafinil] in utero.”
In light of the potential for Provigil and Nuvigil use during pregnancy to cause major birth defects in exposed babies, Teva, in participation with the European Medicines Agency, issued a warning to healthcare providers in June 2019, indicating that “the use of modafinil during pregnancy is suspected to cause congenital malformations.” These birth defect warnings in Canada and Europe came far too late for many women who used Provigil or Nuvigil while pregnant or who became pregnant while using the narcolepsy drugs and subsequently gave birth to babies with birth defects like cleft lip, cleft palate, hypospadias, microcephaly and congenital heart malformations. And for pregnant women and women of childbearing age in the United States, there has yet to be any official warning from Teva or the FDA about the potential for Provigil and Nuvigil to adversely affect a developing fetus. As more information comes to light about the potential pregnancy risks of Provigil and Nuvigil narcolepsy treatment, families across the country caring for children with serious birth defects affecting the heart, face, genitals or head are expected to bring legal claims against Teva Pharmaceuticals, pursuing compensation for medical expenses from surgeries and treatment, pain and suffering, and other damages.